Aztreonam

證據等級: L5

預測適應症: 10 個

Aztreonam: Drug Repurposing Evaluation — Insufficient Data to Proceed

One-Sentence Summary

Aztreonam (DB00355) is a monobactam β-lactam antibiotic used for gram-negative bacterial infections. The current Evidence Pack contains no TxGNN predicted indications, and critical data items — including original indications, mechanism of action, and safety warnings — are not yet populated. A formal repurposing evaluation cannot be completed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available (no regulatory data retrieved)
Predicted New Indication	Not available (no TxGNN output)
TxGNN Prediction Score	N/A
Evidence Level	N/A — no predictions generated
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why Evaluation Cannot Proceed

The Evidence Pack for Aztreonam is missing three categories of data that are all required before any repurposing claim can be assessed:

1. No TxGNN predictions generated. The predicted_indications array is empty. Without a model-predicted target indication, there is no candidate hypothesis to evaluate — every downstream section (evidence review, mechanistic rationale, clinical trial mapping) is contingent on this output.

2. No mechanism of action on record. The original_moa field is flagged as a High-severity data gap. Even if predictions were available, mechanistic plausibility — a core pillar of drug repurposing reasoning — cannot be assessed without knowing how the drug acts at the molecular level.

3. No structured original indication data. The original_indications array is empty and no Finland (Fimea) marketing authorisations exist. While Aztreonam is generally known as a monobactam antibiotic active against aerobic gram-negative bacteria, no structured or regulatory-sourced indication text is available in this pack to anchor the repurposing analysis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Aztreonam is currently not marketed in Finland. Zero marketing authorisations are on record with Fimea.

Safety Considerations

Please refer to the package insert for safety information.

(Safety warnings and contraindications are flagged as a Blocking data gap; DDI query returned no results.)

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no TxGNN predictions and three unresolved data gaps (Blocking: safety warnings; High: MOA; structural: original indications). There is no repurposing hypothesis to evaluate, and safety cannot be assessed for any new indication.

To proceed, the following is needed:

TxGNN model output — re-run the prediction pipeline for DB00355 and populate predicted_indications with scored candidates
Mechanism of action — query the DrugBank API for Aztreonam's pharmacodynamics and target proteins
Package insert safety data — download and parse the Fimea or TFDA package insert to extract warnings, contraindications, and special population guidance
Clarify repurposing scope — confirm whether the intended direction is infectious disease (e.g., resistant gram-negative pathogens, inhaled formulation for cystic fibrosis), or a cross-therapeutic area repurposing experiment, as this will determine which TxGNN disease namespace to query
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.